ZGNX earnings call for the period ending March 31, 2019.
News & Analysis: Zogenix
The pharma company got a rejection letter from the U.S. Food and Drug Administration.
Novartis completed its spin-off of eye care specialist Alcon and Zogenix had a drug application rejected.
The FDA refused to accept the biotech's experimental epilepsy medication for review.
This company's epilepsy drug has been submitted for approval in the U.S. and Europe.
ZGNX earnings call for the period ending December 31, 2018.
The company announced and completed a share offering last month, but the timing worked out well.
Can these hot biotech stocks get even hotter?
Wall Street is cheering the latest data for the company's epilepsy drug.
The market cheered after one of these companies distanced itself from its founder.